

參考資料

1. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Adult Cancer Pain, Version 1.2018. 2018.
2. Ripamonti CI, Santini D, Maranzano E, et al. Management of cancer pain: ESMO Clinical Practice Guidelines. *Ann Oncol* 2012; 23 Suppl 7:viii139-54.
3. Jara C, Del Barco S, Grávalos C, et al. SEOM clinical guideline for treatment of cancer pain (2017). *Clin Transl Oncol* 2018; 20:97-107.
4. Coluzzi F, Taylor R Jr, Pergolizzi JV Jr, et al. Good clinical practice guide for opioids in pain management: the three Ts - titration (trial), tweaking (tailoring), transition (tapering). *Braz J Anesthesiol* 2016; 66:310-7.
5. Scarborough BM, Smith CB. Optimal pain management for patients with cancer in the modern era. *CA Cancer J Clin* 2018; 68:182-96.
6. World Health Organization (WHO). *Cancer Pain Relief with a Guide to Opioid Availability*, 2nd Ed. World Health Organization 1996; Geneva, Switzerland.
7. World Health Organization (WHO). *Cancer Pain Relief*. World Health Press 1986; Geneva, Switzerland.
8. Krames ES. Interventional pain management. Appropriate when less invasive therapies fail to provide adequate analgesia. *Med Clin North Am* 1999; 83:787-808.
9. Miguel R. Interventional treatment of cancer pain: the fourth step in the World Health Organization analgesic ladder? *Cancer Control* 2000; 7:149-56.
10. Thapa D, Rastogi V, Ahuja V, et al. Cancer pain management-current status. *J Anaesthesiol Clin Pharmacol* 2011; 27:162-8.
11. Natoli S, Lazzari M, Dauri M. Open questions in the treatment of cancer pain: time for strong evidence-based approach? *Expert Opin Pharmacother* 2015; 16:1-4.
12. Carlson CL. Effectiveness of the World Health Organization cancer pain relief guidelines: an integrative review. *J Pain Res* 2016; 9:515-34.
13. Mercadante S, Porzio G, Ferrera P, et al. Low morphine doses in opioid-naive cancer patients with pain. *J Pain Symptom Manage* 2006; 31:242-7.
14. Bandieri E, Romero M, Ripamonti CI, et al. Randomized Trial of Low-Dose Morphine Versus Weak Opioids in Moderate Cancer Pain. *J Clin Oncol* 2016; 34:436-42.
15. Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. *Lancet Oncol* 2012; 13:e58-68.
16. World Health Organization (WHO). WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses. World Health Organization 2012; Geneva, Switzerland. Available at: http://apps.who.int/iris/bitstream/handle/10665/44540/9789241548120_Guidelines.pdf;jsessionid=77878D876DD33A98FE90C9DD007EF45B?sequence=1 [Accessed July 02, 2018]
17. Portenoy RK, Ahmed E. Principles of opioid use in cancer pain. *J Clin Oncol* 2014; 32:1662-70.

18. Schuster M, Bayer O, Heid F, et al. Opioid Rotation in Cancer Pain Treatment: A systematic review. *Dtsch Arztebl Int* 2018; 115:135-42.
19. Stone PA, Macintyre PE, Jarvis DA. Norpethidine toxicity and patient controlled analgesia. *Br J Anaesth* 1993; 71:738-40.
20. Seifert CF, Kennedy S. Meperidine is alive and well in the new millennium: evaluation of meperidine usage patterns and frequency of adverse drug reactions. *Pharmacotherapy* 2004; 24:776-83.
21. Bowdle TA. Adverse effects of opioid agonists and agonist-antagonists in anaesthesia. *Drug Saf* 1998; 19:173-89.
22. Liu JG, Prather PL. Chronic agonist treatment converts antagonists into inverse agonists at delta-opioid receptors. *J Pharmacol Exp Ther* 2002; 302:1070-9.
23. Eguchi M. Recent advances in selective opioid receptor agonists and antagonists. *Med Res Rev* 2004; 24:182-212.
24. Wang D, Sun X, Sadee W. Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment. *J Pharmacol Exp Ther* 2007; 321:544-52.
25. Helm S, Trescot AM, Colson J, et al. Opioid antagonists, partial agonists, and agonists/antagonists: the role of office-based detoxification. *Pain Physician* 2008; 11:225-35.
26. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. *Pain* 1990; 41:273-81.
27. Mercadante S, Portenoy RK. Breakthrough cancer pain: twenty-five years of study. *Pain* 2016; 157:2657-63.
28. Fortner BV, Demarco G, Irving G, et al. Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain. *J Pain Symptom Manage* 2002; 24:45-52.
29. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. *Pain* 1999; 81:129-34.
30. Swanwick M, Haworth M, Lennard RF. The prevalence of episodic pain in cancer: a survey of hospice patients on admission. *Palliat Med* 2001; 15:9-18.
31. Greco MT, Corli O, Montanari M, et al. Epidemiology and pattern of care of breakthrough cancer pain in a longitudinal sample of cancer patients: results from the Cancer Pain Outcome Research Study Group. *Clin J Pain* 2011; 27:9-18.
32. Davies A, Buchanan A, Zeppetella G, et al. Breakthrough cancer pain: an observational study of 1000 European oncology patients. *J Pain Symptom Manage* 2013; 46:619-28.
33. Wang CH, Lee SY. Undertreatment of cancer pain. *Acta Anaesthesiol Taiwan* 2015; 53:58-61.
34. ACHEON Working Group, Kim YC, Ahn JS, et al. Current practices in cancer pain management in Asia: a survey of patients and physicians across 10 countries. *Cancer Med* 2015; 4:1196-204.
35. Shen WC, Chen JS, Shao YY, et al. Impact of Undertreatment of Cancer Pain With Analgesic Drugs on Patient Outcomes: A Nationwide Survey of Outpatient Cancer Patient Care in Taiwan. *J Pain Symptom Manage* 2017; 54:55-65.
36. Ho KY, Ahn JS, Calimag MM, et al. Inadequate treatment practices for pain relief and adverse event management in cancer patients across 10

- countries/regions in Asia: a call for greater efforts to improve standards for patient care. *Asia Pac J Clin Oncol* 2018; 14:159-66.
37. Davies AN, Dickman A, Reid C, et al. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. *Eur J Pain* 2009; 13:331-8.
 38. Davies AN, Elsner F, Filbet MJ, et al. Breakthrough cancer pain (BTcP) management: a review of international and national guidelines. *BMJ Support Palliat Care* 2018 Jun 6. doi: 10.1136/bmjspcare-2017-001467. [Epub ahead of print]
 39. Deandrea S, Corli O, Consonni D, et al. Prevalence of breakthrough cancer pain: a systematic review and a pooled analysis of published literature. *J Pain Symptom Manage* 2014; 47:57-76.
 40. Porta-Sales J, Pérez C, Escobar Y, et al. Diagnosis and management of breakthrough cancer pain: Have all the questions been resolved? A Delphi-based consensus assessment (DOIRON). *Clin Transl Oncol* 2016; 18:945-54.
 41. Mercadante S. The use of rapid onset opioids for breakthrough cancer pain: the challenge of its dosing. *Crit Rev Oncol Hematol* 2011; 80:460-5.
 42. Mercadante S, Marchetti P, Cuomo A, et al. Breakthrough pain and its treatment: critical review and recommendations of IOPS (Italian Oncologic Pain Survey) expert group. *Support Care Cancer* 2016; 24:961-8.
 43. Derry S, Wiffen PJ, Moore RA, et al. Oral nonsteroidal anti-inflammatory drugs (NSAIDs) for cancer pain in adults. *Cochrane Database Syst Rev* 2017; 7:CD012638. doi: 10.1002/14651858.CD012638.pub2.
 44. Moselli NM, Cruto M, Massucco P, et al. Long-term continuous subcutaneous infusion of ketoprofen combined with morphine: a safe and effective approach to cancer pain. *Clin J Pain* 2010; 26:267-74.
 45. Antman EM, Bennett JS, Daugherty A, et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. *Circulation* 2007; 115:1634-42.
 46. Wehling M. Non-steroidal anti-inflammatory drug use in chronic pain conditions with special emphasis on the elderly and patients with relevant comorbidities: management and mitigation of risks and adverse effects. *Eur J Clin Pharmacol* 2014; 70:1159-72.
 47. Payne R. Limitations of NSAIDs for pain management: toxicity or lack of efficacy? *J Pain* 2000; 1(3 Suppl):14-8.
 48. Bancos S, Bernard MP, Topham DJ, et al. Ibuprofen and other widely used non-steroidal anti-inflammatory drugs inhibit antibody production in human cells. *Cell Immunol* 2009; 258:18-28.
 49. Whitcomb LA, Kirsh KL, Passik SD. Substance abuse issues in cancer pain. *Curr Pain Headache Rep* 2002; 6:183-90.
 50. Meera A. Pain and Opioid Dependence: Is it a Matter of Concern? *Indian J Palliat Care* 2011; 17(Suppl):S36-8.
 51. Pergolizzi JV, Zampogna G, Taylor R, et al. A Guide for Pain Management in Low and Middle Income Communities. Managing the Risk of Opioid Abuse in Patients with Cancer Pain. *Front Pharmacol*

- 2016; 7:42.
52. International Association for the Study of Pain (IASP). IASP Statement on Opioids. 2018. Available at: <http://www.iasp-pain.org/Advocacy/Content.aspx?ItemNumber=7194> [Accessed July 02, 2018]
 53. Bruera E, Paice JA. Cancer pain management: safe and effective use of opioids. *Am Soc Clin Oncol Educ Book* 2015:e593-9.
 54. Lee JS, Hu HM, Edelman AL, et al. New Persistent Opioid Use Among Patients With Cancer After Curative-Intent Surgery. *J Clin Oncol* 2017; 35:4042-9.
 55. Sutradhar R, Lokku A, Barbera L. Cancer survivorship and opioid prescribing rates: A population-based matched cohort study among individuals with and without a history of cancer. *Cancer* 2017; 123:4286-93.
 56. Tegeder I, Lötsch J, Geisslinger G. Pharmacokinetics of opioids in liver disease. *Clin Pharmacokinet* 1999; 37:17-40.
 57. Chandok N, Watt KD. Pain management in the cirrhotic patient: the clinical challenge. *Mayo Clin Proc* 2010; 85:451-8.
 58. Bosilkovska M, Wlader B, Besson M, et al. Analgesics in patients with hepatic impairment: pharmacology and clinical implications. *Drugs* 2012; 72:1645-69.
 59. Dwyer JP, Jayasekera C, Nicoll A. Analgesia for the cirrhotic patient: a literature review and recommendations. *J Gastroenterol Hepatol* 2014; 29:1356-60.
 60. Imani F, Motavaf M, Safari S, et al. The therapeutic use of analgesics in patients with liver cirrhosis: a literature review and evidence-based recommendations. *Hepat Mon* 2014; 14:e23539.
 61. Gelot S, Nakhla E. Opioid Dosing in Renal and Hepatic Impairment. *US Pharm* 2014; 39:34-8.
 62. Soleimanpour H, Safari S, Shahsavari Nia K, et al. Opioid Drugs in Patients With Liver Disease: A Systematic Review. *Hepat Mon* 2016; 16:e32636.
 63. King S, Forbes K, Hanks GW, et al. A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project. *Palliat Med* 2011; 25:525-52.
 64. Sande TA, Laird BJ, Fallon MT. The use of opioids in cancer patients with renal impairment-a systematic review. *Support Care Cancer* 2017; 25:661-75.
 65. Böger RH. Renal impairment: a challenge for opioid treatment? The role of buprenorphine. *Palliat Med* 2006; 20 Suppl 1:s17-23.
 66. Dean M. Opioids in renal failure and dialysis patients. *J Pain Symptom Manage* 2004; 28:497-504.
 67. Poulsen L, Brøsen K, Arendt-Nielsen L, et al. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. *Eur J Clin Pharmacol* 1996; 51:289-95.
 68. Liao HW, Tsai IL, Chen GY, et al. Simultaneous detection of single nucleotide polymorphisms and copy number variations in the CYP2D6 gene by multiplex polymerase chain reaction combined with capillary electrophoresis. *Anal Chim Acta* 2013; 763:67-75.
 69. Tsai MH, Lin KM, Hsiao MC, et al. Genetic polymorphisms of

- cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response. *Pharmacogenomics* 2010; 11:537-46.
70. Liou YH, Lin CT, Wu YJ, et al. The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population. *J Hum Genet* 2006; 51:857-63.
 71. Electronic Medicines Compendium (eMC). Codeine Phosphate. 2016. Available at: <https://www.medicines.org.uk/emc/product/5753/smpc> [Accessed: July 02, 2018]
 72. Munar MY, Singh H. Drug Dosing Adjustments in Patients with Chronic Kidney Disease. *Am Fam Physician* 2007; 75:1487-96.
 73. Pham PC, Khaing K, Sievers TM, et al. 2017 update on pain management in patients with chronic kidney disease. *Clin Kidney J* 2017; 10:688-97.
 74. Electronic Medicines Compendium (eMC). Tramadol hydrochloride. 2017. Available at: <https://www.medicines.org.uk/emc/product/5924/smpc> [Accessed: July 02, 2018]
 75. Electronic Medicines Compendium (eMC). Tramadol hydrochloride 37.5 mg + Acetaminophen 325 mg. 2017. Available at: <https://www.medicines.org.uk/emc/product/6630/smpc> [Accessed: July 02, 2018]
 76. Hoskin PJ, Hanks GW, Aherne GW, et al. The bioavailability and pharmacokinetics of morphine after intravenous, oral and buccal administration in healthy volunteers. *Br J Clin Pharmacol* 1989; 27:499-505.
 77. Halbsguth U, Rentsch KM, Eich-Höchli D, et al. Oral diacetylmorphine (heroin) yields greater morphine bioavailability than oral morphine: bioavailability related to dosage and prior opioid exposure. *Br J Clin Pharmacol* 2008; 66:781-91.
 78. Klepstad P, Kaasa S, Jystad A, et al. Immediate- or sustained-release morphine for dose finding during start of morphine to cancer patients: a randomized, double-blind trial. *Pain* 2003; 101:193-8.
 79. Harris JT, Suresh Kumar K, Rajagopal MR. Intravenous morphine for rapid control of severe cancer pain. *Palliat Med* 2003; 17:248-56.
 80. Murray A, Hagen NA. Hydromorphone. *J Pain Symptom Manage* 2005; 29:S57-66.
 81. Gardner-Nix J, Mercadante S. The role of OROS hydromorphone in the management of cancer pain. *Pain Pract* 2010; 10:72-7.
 82. Sathyan G, Sivakumar K, Thippawong J. Pharmacokinetic profile of a 24-hour controlled release OROS formulation of hydromorphone in the presence of alcohol. *Curr Med Res Opin* 2008; 24:297-305.
 83. Gupta S, Sathyan G. Providing Constant Analgesia with OROS® Hydromorphone. *J Pain Symp Manage* 2007; 33:S19-24.
 84. Grider JS. Clinical application of extended-release hydromorphone for pain management. *Therapy* 2009; 6:653-6.
 85. Gaskell H, Derry S, Stannard C, et al. Oxycodone for neuropathic pain in adults. *Cochrane Database Syst Rev* 2016; 7:CD010692.
 86. Kummer O, Hammann F, Moser C, et al. Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. *Eur J Clin Pharmacol* 2011; 67:63-71.
 87. Heiskanen TE, Ruismäki PM, Seppälä TA, et al. Morphine or oxycodone in cancer pain? *Acta Oncol* 2000; 39:941-7.

88. Andreassen TN, Klepstad P, Davies A, et al. Is oxycodone efficacy reflected in serum concentrations? A multicenter, cross-sectional study in 456 adult cancer patients. *J Pain Symptom Manage* 2012; 43:694-705.
89. Schmidt-Hansen M, Bennett MI, Arnold S, et al. Oxycodone for cancer-related pain. *Cochrane Database Syst Rev* 2017; 8:CD003870.
90. Biancofiore G. Oxycodone controlled release in cancer pain management. *Ther Clin Risk Manag* 2006; 2:229-34.
91. Labroo RB, Paine MF, Thummel KE, et al. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions. *Drug Metab Dispos* 1997; 25:1072-80.
92. Kuip EJ, Zandvliet ML, Koolen SL, et al. A review of factors explaining variability in fentanyl pharmacokinetics; focus on implications for cancer patients. *Br J Clin Pharmacol* 2017; 83:294-313.
93. Staats PS, Markowitz J, Schein J. Incidence of constipation associated with long-acting opioid therapy: a comparative study. *South Med J* 2004; 97:129-34.
94. Minami S, Kijima T, Nakatani T, et al. Opioid switch from low dose of oral oxycodone to transdermal fentanyl matrix patch for patients with stable thoracic malignancy-related pain. *BMC Palliat Care* 2014; 13:46.
95. Freynhagen R, von Giesen HJ, Busche P, et al. Switching from reservoir to matrix systems for the transdermal delivery of fentanyl: a prospective, multicenter pilot study in outpatients with chronic pain. *J Pain Symptom Manage* 2005; 30:289-97.
96. Smith H. A Comprehensive Review of Rapid-Onset Opioids for Breakthrough Pain. *CNS Drugs* 2012; 26:509-35.
97. Vasisht N, Gever LN, Tagarro I, et al. Formulation selection and pharmacokinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: a randomized, open-label, single-dose, crossover study. *Clin Drug Investig* 2009; 29:647-54.
98. Rauck R, North J, Gever LN, et al. Fentanyl buccal soluble film (FBFSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study. *Ann Oncol* 2010; 21:1308-14.
99. Taylor DR. Fentanyl buccal tablet: rapid relief from breakthrough pain. *Expert Opin Pharmacother* 2007; 8:3043-51.
100. Slatkin NE, Xie F, Messina J, et al. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. *J Support Oncol* 2007; 5:327-34.
101. Foster B, Twycross R, Mihalyo M, et al. Buprenorphine. *J Pain Symptom Manage* 2013; 45:939-49.
102. Plante GE, VanItallie TB. Opioids for cancer pain: the challenge of optimizing treatment. *Metabolism* 2010; 59 Suppl 1:S47-52.
103. Cone EJ, Gorodetzky CW, Yousefnejad D, et al. The metabolism and excretion of buprenorphine in humans. *Drug Metab Dispos* 1984; 12:577-81.
104. Filitz J, Griessinger N, Sittl R, et al. Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine. *Eur J Pain* 2006; 10:743-8.
105. Vadivelu N, Hines RL. Management of chronic pain in the elderly:

- focus on transdermal buprenorphine. *Clin Interv Aging* 2008; 3:421-30.
106. Khanna IK, Pillarisetti S. Buprenorphine - an attractive opioid with underutilized potential in treatment of chronic pain. *J Pain Res* 2015; 8:859-70.
 107. Greenwald MK, Johanson CE, Moody DE, et al. Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. *Neuropsychopharmacology* 2003; 28:2000-9.
 108. Pergolizzi J, Aloisi AM, Dahan A, et al. Current knowledge of buprenorphine and its unique pharmacological profile. *Pain Pract* 2010; 10:428-50.
 109. Pergolizzi JV Jr, Mercadante S, Echaburu AV, et al. The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus. *Curr Med Res Opin* 2009; 25:1517-28.
 110. Johnson RE, Fudala PJ, Payne R. Buprenorphine: considerations for pain management. *J Pain Symptom Manage* 2005; 29:297-326.
 111. Aurilio C, Pace MC, Pota V, et al. Opioids switching with transdermal systems in chronic cancer pain. *J Exp Clin Cancer Res* 2009; 28:61.
 112. Schmidt-Hansen M, Bromham N, Taubert M, et al. Buprenorphine for treating cancer pain. *Cochrane Database Syst Rev* 2015; (3):CD009596.
 113. Hagen NA, Foley KM, Cerbone DJ, et al. Chronic nausea and morphine-6-glucuronide. *J Pain Symptom Manage* 1991; 6:125-8.
 114. Janicki PK. Pharmacology of morphine metabolites. *Curr Pain Headache Rep* 1997; 1:264-70.
 115. Lötsch J. Opioid metabolites. *J Pain Symptom Manage* 2005; 29(5 Suppl):S10-24.